Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
AstraZeneca
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
AstraZeneca
Novartis
Pfizer
Hoffmann-La Roche
Amgen
Eli Lilly and Company
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Pfizer
Sichuan Baili Pharmaceutical Co., Ltd.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Pfizer
RemeGen Co., Ltd.
Merck Sharp & Dohme LLC
SWOG Cancer Research Network
Merck Sharp & Dohme LLC
Sichuan Baili Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
InSightec
AstraZeneca
ArriVent BioPharma, Inc.
Achieve Life Sciences
ImmunityBio, Inc.
ImmunityBio, Inc.
Bristol-Myers Squibb
AbbVie
OncoC4, Inc.
Vastra Gotaland Region
Canadian Cancer Trials Group
ETOP IBCSG Partners Foundation
Nuvation Bio Inc.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Nuvation Bio Inc.